Rheumatoid arthritis related interstitial lung disease

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2015;41(2):225–236.
   PubMed Web of Science ®Google Scholar
• Raimundo K, Solomon JJ, Olson AL, et al. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol. 2019;46(4):360–369.
   PubMed Web of Science ®Google Scholar
• Wallis A, Spinks K. The diagnosis and management of interstitial lung diseases. BMJ. 2015;350(may07 17):1–12.
   Google Scholar
• Hyldgaard C, Hilberg O, Pedersen AB, et al., A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 76(1700–1706): 1700–1706. 2017.
   PubMedGoogle Scholar
• Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–1591.
   PubMed Web of Science ®Google Scholar
• Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicentre UK study. Rheumatol (United Kingdom). 2014;53:1676–1682.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis. 2015;7(6):247–267.
   PubMed Web of Science ®Google Scholar
• Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56(8):622–627.
   PubMed Web of Science ®Google Scholar
• Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159–166.
   PubMedGoogle Scholar
• Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156(2):528–535.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Vacchi C, Cassone G, et al. Interstitial lung disease related to rheumatoid arthritis. What do we don’t know? The LIRA study (Lung Involvement in Rheumatoid Arthritis). Ann Rheum Dis. 2020;79:290–291.
   Google Scholar
• Myasoedova E, Davis JM, Crowson CS, et al. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12(5):379–385.
   PubMedGoogle Scholar
• Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology. 2010;49(8):1483–1489.
   PubMed Web of Science ®Google Scholar
• Yin Y, Liang D, Zhao L, et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One. 2014;9:1–6.
   Web of Science ®Google Scholar
• Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106(11):1591–1599.
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191(12):1403–1412.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li H, Wu N, et al. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2017;36(4):817–823.
   PubMed Web of Science ®Google Scholar
• Correia CS, Briones MR, Guo R, et al. Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clin Rheumatol. 2019;38(4):1201–1206.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Manfredi A, Cerri S, et al. Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease. Clin Exp Rheumatol. 2016;34(3):564–565.
   PubMed Web of Science ®Google Scholar
• Harlow L, Rosas IO, Gochuico BR, et al. Identification of citrullinated Hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2013;65(4):869–879.
   PubMedGoogle Scholar
• Wang J, Devenport J, Low JM, et al. Relationship between baseline and early changes in c-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res. 2016;68(6):882–885.
   PubMed Web of Science ®Google Scholar
• Chen J, Doyle TJ, Liu Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015;67(1):28–38.
   PubMed Web of Science ®Google Scholar
• Liao KP, Sparks JA, Hejblum BP, et al. Phenome-wide association study of autoantibodies to citrullinated and noncitrullinated epitopes in rheumatoid arthritis. Arthritis Rheumatol. 2017;69(4):742–749.
   PubMed Web of Science ®Google Scholar
• Wu X, Xu L, Cheng Q, et al. Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study. Respir Med. 2020;166:1–5.
   Web of Science ®Google Scholar
• Avouac J, Cauvet A, Steelandt A, et al. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS One. 2020;15(5):1–11.
   Web of Science ®Google Scholar
• Spagnolo P, Grunewald J, Du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir Med. 2014;2(5):416–428.
   PubMed Web of Science ®Google Scholar
• Juge P-A, Borie R, Kannengiesser C, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J. 2017;49(5):1602314.
   PubMed Web of Science ®Google Scholar
• Paulin F, Doyle TJ, Fletcher EA, et al. Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis: shared mechanistic and phenotypic traits suggest overlapping disease mechanisms. Rev Invest Clin. 2015;67(5):280.
   PubMedGoogle Scholar
• Giles JT, Darrah E, Danoff S, et al. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One. 2014;9(6):e98794.
   PubMed Web of Science ®Google Scholar
• Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014;26(1):64–71.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Luppi F, Cassone G, et al. Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. Expert Rev Clin Immunol. 2020;16(8):751–770.
   PubMed Web of Science ®Google Scholar
• Pierer M, Wagner U, Rossol M, et al. Toll-like receptor 4 is involved in inflammatory and joint destructive pathways in collagen-induced arthritis in DBA1J mice. PLoS One. 2011;6(8):e23539.
   PubMed Web of Science ®Google Scholar
• Karampitsakos T, Woolard T, Bouros D, et al. Toll-like receptors in the pathogenesis of pulmonary fibrosis. Eur J Pharmacol. 2017;808:35–43.
   PubMed Web of Science ®Google Scholar
• Go H, Koh J, Kim HS, et al. Expression of toll-like receptor 2 and 4 is increased in the respiratory epithelial cells of chronic idiopathic interstitial pneumonia patients. Respir Med. 2014;108(5):783–792.
   PubMed Web of Science ®Google Scholar
• Sacre SM, Drexler SK, Andreakos E, et al. Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann Rheum Dis. 2007;66(Supplement 3):iii81–iii86.
   PubMedGoogle Scholar
• Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544–1554.
   PubMed Web of Science ®Google Scholar
• Dai Y, Wang W, Yu Y, et al. Rheumatoid arthritis–associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol. 2020;40(4):1211–1220.
   PubMed Web of Science ®Google Scholar
• Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–1512.
   PubMed Web of Science ®Google Scholar
• Juge PA, Lee JS, Ebstein E, et al., MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 379(23): 2209–2219. 2018.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang J, Lau J, et al. Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(10):581–596.
   PubMed Web of Science ®Google Scholar
• Oka S, Furukawa H, Shimada K, et al. Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease. BMC Musculoskelet Disord. 2017;18(1):1–7.
   PubMedGoogle Scholar
• Zhou W, Zheng J, Yuan M, et al. Differentially expressed lncRNAs in peripheral blood mononuclear cells from middle-aged female patients with rheumatoid arthritis–associated interstitial lung disease. Clin Rheumatol. 2020;39(8):2281–2289.
   PubMed Web of Science ®Google Scholar
• Cavagna L, Monti S, Grosso V, et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int. 2013;2013:1–13.
   Web of Science ®Google Scholar
• Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Prim. 2017;3(1):17074.
   PubMedGoogle Scholar
• Solomon JJ, Fischer A. Connective tissue disease-associated interstitial lung disease: a focused review. J Intensive Care Med. 2015;30(7):392–400.
   PubMed Web of Science ®Google Scholar
• Messina R, Guggino G, Benfante A, et al. Interstitial lung disease in elderly rheumatoid arthritis patients. Drugs Aging. 2020;37(1):11–18.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Cassone G, Cerri S, et al., Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device). BMC Pulm Med. 19(1): 111. 2019.
   PubMedGoogle Scholar
• Sgalla G, Walsh SLF, Sverzellati N, et al. “Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC Pulm Med. 2018;18(1):103.
   PubMedGoogle Scholar
• Luppi F, Cerri S, Taddei S, et al. Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Intern Emerg Med. 2015;10(4):401–411.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al., Acute exacerbation of idiopathic pulmonary fibrosis an international working group report. Am J Respir Crit Care Med. 194(3): 265–275. 2016.
   PubMed Web of Science ®Google Scholar
• Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009;103(6):846–853.
   PubMed Web of Science ®Google Scholar
• Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132(1):214–220.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Sebastiani M, Cerri S, et al., Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. J Thorac Dis. 11(4): 1621–1628. 2019.
   PubMed Web of Science ®Google Scholar
• Silva CIS, Müller NL. Interstitial lung disease in the setting of collagen vascular disease. Semin Roentgenol. 2010;45(1):22–28.
   PubMed Web of Science ®Google Scholar
• Esposito AJ, Chu SG, Madan R, et al. Thoracic manifestations of rheumatoid arthritis. Clin. Chest Med. W.B. Saunders. 2019;40(3):545–560.
   PubMed Web of Science ®Google Scholar
• Paschalaki KE, Jacob J, Wells AU. Monitoring of lung involvement in rheumatologic disease. Respiration. 2016;91(2):89–98.
   PubMed Web of Science ®Google Scholar
• Cottin V, Richeldi L. Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. Eur Respir Rev. 2014;23(131):106–110.
   PubMedGoogle Scholar
• Cottin V, Cordier J-F. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J. 2012;40(3):519–521.
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Soto-Fajardo C, Pineda C, et al. Ultrasound in the assessment of interstitial lung disease in systemic sclerosis: a systematic literature review by the OMERACT ultrasound group. J Rheumatol. 2020;47(7):991–1000.
   PubMed Web of Science ®Google Scholar
• Moazedi-Fuerst FC, Kielhauser SM, Scheidl S, et al. Ultrasound screening for interstitial lung disease in rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(2):199–203.
   PubMed Web of Science ®Google Scholar
• Cogliati C, Antivalle M, Torzillo D, et al. Standard and pocket-size lung ultrasound devices can detect interstitial lung disease in rheumatoid arthritis patients. Rheumatology. 2014;53(8):1497–1503.
   PubMed Web of Science ®Google Scholar
• Ciancio N, Pavone M, Torrisi SE, et al. Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidiscip Respir Med. 2019;14(1):17.
   PubMedGoogle Scholar
• Jacob J, Song JW, Yoon H-Y, et al. Prevalence and effects of emphysema in never-smokers with rheumatoid arthritis interstitial lung disease. EBioMedicine. 2018;28:303–310.
   PubMed Web of Science ®Google Scholar
• Robles-Pérez A, Luburich P, Bolivar S, et al. A prospective study of lung disease in a cohort of early rheumatoid arthritis patients. Sci Rep. 2020;10(1):15640.
   PubMedGoogle Scholar
• Fayed H, Coghlan JG. Pulmonary hypertension associated with connective tissue disease. Semin Respir Crit Care Med. 2019;40(2):173–183.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174(7):803–809.
   PubMed Web of Science ®Google Scholar
• Wells AU, Denton CP. Interstitial lung disease in connective tissue disease - Mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–739.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• Levi Y, Israeli-Shani L, Kuchuk M, et al. Rheumatological assessment is important for interstitial lung disease diagnosis. J Rheumatol. 2018;45(11):1509–1514.
   PubMed Web of Science ®Google Scholar
• Furini F, Carnevale A, Casoni GL, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. Front Med. 2019;6:246.
   PubMed Web of Science ®Google Scholar
• Wells A, Devaraj A, Renzoni EA, et al., Multidisciplinary evaluation in patients with lung disease associated with connective tissue disease. Semin Respir Crit Care Med. 40(2): 184–193. 2019.
   PubMed Web of Science ®Google Scholar
• Martín-Martínez MA, Castañeda S, Sánchez-Alonso F, et al. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study—results at 5 years of follow-up. Rheumatology 2020 keaa737 10.1093/rheumatology/keaa737
   PubMedGoogle Scholar
• Cassone G, Manfredi A, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020;9(4):1082.
   Web of Science ®Google Scholar
• Barnett J, Devaraj A. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med. 2019;40(2):159–172.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232(1):81–91.
   PubMed Web of Science ®Google Scholar
• Ahuja J, Arora D, Kanne JP, et al. Imaging of pulmonary manifestations of connective tissue diseases. Radiol Clin North Am. 2016;54(6):1015–1031.
   PubMed Web of Science ®Google Scholar
• Jacob J, Hirani N, Chm VM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J. 2019;53(1):1800869.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med. 2013;107(8):1247–1252.
   PubMed Web of Science ®Google Scholar
• Chung JH, Cox CW, Montner SM, et al. CT features of the usual interstitial pneumonia pattern: differentiating connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis. Am J Roentgenol. 2018;210(2):307–313.
   PubMed Web of Science ®Google Scholar
• Corcoran JP, Ahmad M, Mukherjee R, et al. Pleuro-pulmonary complications of rheumatoid arthritis. Respir Care. 2014;59(4):e55–e59.
   PubMed Web of Science ®Google Scholar
• Ej K, Hr C, Te K. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136(5):1397–1405.
   PubMed Web of Science ®Google Scholar
• Lee H-K, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019–2027.
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Sprunger DB, et al., Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 183(3): 372–378. 2011.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37(6):1411–1417.
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology. 2017;56(3):344–350.
   PubMed Web of Science ®Google Scholar
• Yamakawa H, Sato S, Tsumiyama E, et al. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria. J Thorac Dis. 2019;11(12):5247–5257.
   PubMed Web of Science ®Google Scholar
• Singh N, Varghese J, England BR, et al. Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: a systematic literature review and meta-analysis. Semin Arthritis Rheum. 2019;49(3):358–365.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47(2):588–596.
   PubMed Web of Science ®Google Scholar
• Kakutani T, Hashimoto A, Tominaga A, et al. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2020;30(3):458–464.
   PubMed Web of Science ®Google Scholar
• Fischer A, Lee JS, Cottin V. Interstitial lung disease evaluation: detecting connective tissue disease. Respiration. 2015;90(3):177–184.
   PubMed Web of Science ®Google Scholar
• Morisset J, Lee JS. New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern? Curr Opin Pulm Med. 2019;25(5):442–449.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Faverio P, Manfredi A, et al. Interstitial pneumonia with autoimmune features: why rheumatologist–pulmonologist collaboration is essential. Biomedicines. 2020;9(1):17.
   PubMed Web of Science ®Google Scholar
• Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–987.
   PubMed Web of Science ®Google Scholar
• Sambataro G, Sambataro D, Torrisi SE, et al. State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. Eur Respir Rev. 2018;27(148):27.
   Web of Science ®Google Scholar
• Cavagna L, Castañeda S, Sciré C, et al. Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria. Ann Rheum Dis. 2018;77(8):e50.
   PubMed Web of Science ®Google Scholar
• Cavagna T-A, Meloni, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. 2019;8(11):2013.
   Web of Science ®Google Scholar
• Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013;8(4):e60442.
   PubMed Web of Science ®Google Scholar
• Luppi F, Sebastiani M, Sverzellati N, et al. Lung complications of Sjogren syndrome. Eur Respir Rev. 2020;29(157):1–17.
   Web of Science ®Google Scholar
• Manfredi A, Sebastiani M, Cerri S, et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clin Rheumatol. 2017;36(6):1261-1268.
   Web of Science ®Google Scholar
• Shariatmaghani S, Salari R, Sahebari M, et al. Musculoskeletal manifestations of sarcoidosis: a review article. Curr Rheumatol Rev. 2018;15(2):83–89.
   Web of Science ®Google Scholar
• Silva-Carmona M, Vogel TP. Genetic disorders should be considered prior to diagnosing interstitial pneumonia with autoimmune features: comment on the review by Wilfong et al. Arthritis Rheumatol. 2019;71(12):2132–2133.
   PubMed Web of Science ®Google Scholar
• Tsui JL, Estrada OA, Deng Z, et al. Analysis of pulmonary features and treatment approaches in the COPA syndrome. ERJ Open Res. 2018;4(2):00017–02018.
   PubMedGoogle Scholar
• Brito Y, Glassberg MK, Ascherman DP. Rheumatoid arthritis-associated interstitial lung disease: current concepts. Curr Rheumatol Rep. 2017;19(12):79.
   PubMed Web of Science ®Google Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613–626.
   PubMed Web of Science ®Google Scholar
• Olivas-Flores EM. Interstitial lung disease in rheumatoid arthritis: current concepts in pathogenesis, diagnosis and therapeutics. World J Rheumatol. 2015;5(1):1.
   Google Scholar
• Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015;2016(68):1–25.
   Google Scholar
• Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology. 2019;58:e3–e42.
   PubMed Web of Science ®Google Scholar
• Grupo de trabajo de la GUIPCAR. GUIPCAR Guía de Práctica Clínica para el Manejo de los Pacientes con Artritis Reumatoide, actualización 2019. 2019.
   Google Scholar
• Rojas-Serrano J, González-Velásquez E, Mejía M, et al. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. Reumatol Clínica. 2012;8(2):68–71.
   PubMedGoogle Scholar
• Fragoulis GE, Nikiphorou E, Larsen J, et al. Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. Front Med. 2019;6:238.
   PubMed Web of Science ®Google Scholar
• Conway R, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis. Panminerva Med. 2017;59(1):33–46.
   PubMed Web of Science ®Google Scholar
• Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9(5):1–12.
   PubMed Web of Science ®Google Scholar
• Sueoka N, Sueoka E, Miyazaki Y, et al. Molecular pathogenesis of interstitial pneumonitis with TNF-alpha transgenic mice. Cytokine. 1998;10(2):124–131.
   PubMed Web of Science ®Google Scholar
• Hou J, Ma T, Cao H, et al. TNF-α-induced NF-κB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis. J Cell Physiol. 2018;233(3):2409–2419.
   PubMed Web of Science ®Google Scholar
• Ortiz LA, Lasky J, Hamilton RF, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res. 1998;24(6):721–743.
   PubMed Web of Science ®Google Scholar
• Nakashita T, Ando K, Kaneko N, et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4(8):e005615.
   PubMed Web of Science ®Google Scholar
• Detorakis EE, Magkanas E, Lasithiotaki I, et al. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents. Clin Exp Rheumatol. 2017;35:43–52.
   PubMed Web of Science ®Google Scholar
• Braun-Moscovici Y, Butbul-Aviel Y, Guralnik L, et al. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int. 2013;33(6):1495–1504.
   PubMed Web of Science ®Google Scholar
• Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology. 2012;51(4):653–662.
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348–1357.
   PubMed Web of Science ®Google Scholar
• Druce KL, Iqbal K, Watson KD, et al. Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open. 2017;3(1):e000473.
   PubMed Web of Science ®Google Scholar
• Gallelli L, Falcone D, Pelaia G, et al. Interleukin-6 receptor superantagonist Sant7 inhibits TGF-β-induced proliferation of human lung fibroblasts. Cell Prolif. 2008;41(3):393–407.
   PubMed Web of Science ®Google Scholar
• Kawashiri S, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int. 2012;32(12):4023–4026.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Kaneko Y, Yamaoka K, et al. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case–control study. Rheumatol Int. 2016;36(6):881–889.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Cassone G, Furini F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J. 2020;50(9):1085–1090.
   PubMed Web of Science ®Google Scholar
• Boleto G, Guignabert C, Pezet S, et al. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Res Ther. 2018;20(1):197.
   PubMedGoogle Scholar
• Nakashita T, Ando K, Takahashi K, et al. Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. Respir Investig. 2016;54(5):376–379.
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Ikari K, Yano K, et al. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. Mod Rheumatol. 2019;29(3):413–417.
   Web of Science ®Google Scholar
• Cassone G, Manfredi A, Atzeni F, et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study. J Clin Med. 2020;9(1):277.
   Web of Science ®Google Scholar
• Fernández-Díaz C, Castañeda S, Melero-González RB, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology. 2020;59(12):3906–3916.
   PubMed Web of Science ®Google Scholar
• Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology. 2019;58(Supplement_1):i34–i42.
   PubMedGoogle Scholar
• Citera G, Mysler E, Madariaga H, et al. Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients. JCR J Clin Rheumatol. 2020; Publish Ah. Publish Ahead of Print 10.1097/RHU.0000000000001552
   Google Scholar
• Sendo S, Saegusa J, Yamada H, et al. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice. Arthritis Res Ther. 2019;21(1):184.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.
   PubMed Web of Science ®Google Scholar
• Luppi F, Spagnolo P, Cerri S, et al. The big clinical trials in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2012;18(5):428–432.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727.
   PubMed Web of Science ®Google Scholar
• Behr J, Neuser P, Prasse A, et al. Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med. 2017;17(1):1–9.
   PubMedGoogle Scholar
• Solomon JJ, Danoff SK, Goldberg HJ, et al. The design and rationale of the trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease. Adv Ther. 2019;36(11):3279–3287.
   PubMed Web of Science ®Google Scholar
• Cassone G, Sebastiani M, Vacchi C, et al. Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming? 2020;30:101051. Respir Med Case Reports.
   PubMed Web of Science ®Google Scholar
• Vacchi C, Manfredi A, Cassone G, et al. Combination therapy with nintedanib and sarilumab for the management of rheumatoid arthritis related interstitial lung disease. Case Rep Med. 2020;2020:1–4.
   Web of Science ®Google Scholar
• Ota M, Iwasaki Y, Harada H, et al. Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2017;27(1):22–28.
   PubMed Web of Science ®Google Scholar
• Toyoda Y, Hanibuchi M, Kishi J, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Investig. 2016;63(3.4):294–299.
   PubMed Web of Science ®Google Scholar
• Marchioni A, Tonelli R, Ball L, et al. Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome? Crit Care. 2018;22(1):80.
   PubMedGoogle Scholar
• Courtwright AM, El-Chemaly S, Dellaripa PF, et al. Survival and outcomes after lung transplantation for non-scleroderma connective tissue–related interstitial lung disease. J Heart Lung Transplant. 2017;36(7):763–769.
   PubMed Web of Science ®Google Scholar
• Ferrara G, Luppi F, Birring SS, et al. Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. Eur Respir Rev. 2018;27(147):170076.
   PubMed Web of Science ®Google Scholar
• Naji NA, Connor MC, Donnelly SC, et al. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil. 2006;26(4):237–243.
   PubMedGoogle Scholar
• Holland AE, Hill CJ, Conron M, Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549–554.
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Heijstek MW, et al. Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019;2020(79):39–52.
   Google Scholar